Disease · MONDO_0002050

depressive disorder

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. depressive disorder. Diseases, record MONDO_0002050. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0002050

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: depressive disorder; Open Targets
Open Targets ID: MONDO_0002050; Open Targets
Other names: depression; Open Targets
Disease Ontology: DOID:1596; Disease Ontology
MeSH: D003866; MeSH
NCI Thesaurus: C2982; NCI Thesaurus
Highest stage of its drugs: Approval, for 42 of its 301 drugs, from ClinicalTrials.gov, DailyMed, EMA Human Drugs, PMDA and TTD; Open Targets

Drugs301

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
SERTRALINE	CHEMBL809	Small molecule	Approval	TTD	55	54	54	Drugs and targets
ESKETAMINE	CHEMBL395091	Small molecule	Approval	ClinicalTrials.gov and EMA Human Drugs	38	36	36	Drugs and targets
FLUOXETINE	CHEMBL41	Small molecule	Approval	TTD	35	33	33	Drugs and targets
CITALOPRAM	CHEMBL549	Small molecule	Approval	TTD	24	23	23	Drugs and targets
DULOXETINE	CHEMBL1175	Small molecule	Approval	TTD	23	22	22	Drugs and targets
VENLAFAXINE	CHEMBL637	Small molecule	Approval	TTD	21	20	20	Drugs and targets
PAROXETINE	CHEMBL490	Small molecule	Approval	TTD	15	14	14	Drugs and targets
MIRTAZAPINE	CHEMBL654	Small molecule	Approval	PMDA and TTD	15	13	13	Drugs and targets
VENLAFAXINE HYDROCHLORIDE	CHEMBL1201066	Small molecule	Approval	PMDA	10	9	9	Drugs and targets
OLANZAPINE	CHEMBL715	Small molecule	Approval	TTD	8	7	7	Drugs and targets

1 to 10 of 301

See all 301 drugs

Targets308

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
SLC6A4	Monoamine transporter	33	Monoamine transporter inhibitor; Serotonin transporter antagonist; Serotonin transporter inhibitor; Sodium-dependent serotonin transporter releasing agent	Approval	https://conductscience.org/library/genes/6532	Drugs and targets
SLC6A2	Monoamine transporter	26	Monoamine transporter inhibitor; Norepinephrine transporter inhibitor; Norepinephrine transporter releasing agent; Sodium-dependent noradrenaline transporter releasing agent	Approval	https://conductscience.org/library/genes/6530	Drugs and targets
HTR2A	5-hydroxytryptamine receptor 2A	20	Serotonin (5-HT) receptor antagonist; Serotonin 2 (5-HT2) receptor antagonist; Serotonin 2a (5-HT2a) receptor agonist; Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2a (5-HT2a) receptor inverse agonist	Approval	https://conductscience.org/library/genes/3356	Drugs and targets
DRD2	D(2) dopamine receptor	15	D2-like dopamine receptor agonist; D2-like dopamine receptor antagonist; Dopamine D1 and D2 receptor agonist; Dopamine D2 receptor antagonist; Dopamine D2 receptor partial agonist; Dopamine receptors; D2 & D3 antagonist	Approval	https://conductscience.org/library/genes/1813	Drugs and targets
HTR2C	5-hydroxytryptamine receptor 2C	14	Serotonin (5-HT) receptor antagonist; Serotonin 2 (5-HT2) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist	Approval	https://conductscience.org/library/genes/3358	Drugs and targets
GABRA1	GABA A receptor alpha-1/beta-1/gamma-2	13	GABA A receptor alpha-1/beta-1/gamma-2 positive allosteric modulator; GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Approval	https://conductscience.org/library/genes/2554	Drugs and targets
GABRB1	GABA A receptor alpha-1/beta-1/gamma-2	13	GABA A receptor alpha-1/beta-1/gamma-2 positive allosteric modulator; GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Approval	https://conductscience.org/library/genes/2560	Drugs and targets
GABRG2	GABA A receptor alpha-1/beta-1/gamma-2	13	GABA A receptor alpha-1/beta-1/gamma-2 positive allosteric modulator; GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Approval	https://conductscience.org/library/genes/2566	Drugs and targets
GABRA2	GABA-A receptor; anion channel	12	GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Approval	https://conductscience.org/library/genes/2555	Drugs and targets
GABRA3	GABA-A receptor; anion channel	12	GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Approval	https://conductscience.org/library/genes/2556	Drugs and targets

1 to 10 of 308

See all 308 targets

Trials599

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 34 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT05932407	A Database Survey of Comparison The Risk of Haemorrhage Between Vortioxetine Tablet Treatment and Selective Serotonin Reuptake Inhibitor (SSRI) Treatment in Participants With Depression		147,777	2025-03-03	Major Depressive Disorder	VORTIOXETINE	Its record names the disease	ClinicalTrials.gov
NCT02775864	Comparative Effectiveness of Adaptive Treatment Strategies for Schizophrenia		81,921	2019-06-07	Schizophrenia, Schizoaffective Disorder	BENZODIAZEPINE	Its record names the disease	ClinicalTrials.gov
NCT01302080	Sertraline Pediatric Registry for the Evaluation of Safety (SPRITES)		941	2021-10-08	Obsessive Compulsive Disorder	SERTRALINE	Its record names the disease	ClinicalTrials.gov
NCT00668525	Escitalopram in Adult Patients With Major Depressive Disorder	Phase 3	877	2010-05-06	Major Depressive Disorder	ESCITALOPRAM	Its record names the disease	ClinicalTrials.gov
NCT02497287	A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression	Phase 3	802	2019-04-29	Treatment-resistant Depression	DULOXETINE, ESCITALOPRAM, ESKETAMINE, SERTRALINE, VENLAFAXINE	Its record names the disease	ClinicalTrials.gov
NCT00789854	Comparing Quetiapine XR Monotherapy and Augmentation With Lithium Augmentation in TRD Patients	Phase 3	688	2012-05-23	Major Depressive Disorder, Treatment Resistant Depression	LITHIUM, QUETIAPINE, SEROTONIN, VENLAFAXINE	Its record names the disease	ClinicalTrials.gov
NCT04345471	A Study of MD-120 in Patients With Depression	Phase 3	615	2024-02-29	Major Depressive Disorder	DESVENLAFAXINE	Its record names the disease	ClinicalTrials.gov
NCT00672958	Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Adults With Major Depressive Disorder	Phase 3	600	2013-12-13	Major Depressive Disorder	VORTIOXETINE	Its record names the disease	ClinicalTrials.gov
NCT01255787	Efficacy and Safety Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive Disorder	Phase 2/3	600	2013-12-18	Depressive Disorder, Major	VORTIOXETINE	Its record names the disease	ClinicalTrials.gov
NCT00401726	Open-Label, Randomized Study Evaluating Treatment With Venlafaxine Extended-Release Plus Dialogues Time to Talk Program	Phase 4	537	2010-06-29	Depressive Disorder, Major	VENLAFAXINE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 599

See all 599 trials

Comparisons in its trials186

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Vortioxetine Treatment vs SSRI Treatment: Number of Participants Who Experienced of Intracranial Hemorrhage in Total Follow-up Period	2 of 22,827	25 of 124,950	147,777	NCT05932407	Trial comparisons
FSC Cohort vs AC Cohort: Number of Participants With Any Chronic Obstructive Pulmonary Disease (COPD)-Related Exacerbation	200 of 1,078	674 of 2,923	4,001	NCT01337336	Trial comparisons
Vortioxetine vs Placebo: serious adverse events	7 of 299	4 of 298	597	NCT00672958	Trial comparisons
Venlafaxine Extended Release (ER) vs Venlafaxine Extended Release (ER) Plus Dialogues: serious adverse events	10 of 269	18 of 268	537	NCT00401726	Trial comparisons
Venlafaxine Extended Release (ER) vs Venlafaxine Extended Release (ER) Plus Dialogues: Number of Patients Compliant With Therapy	248 of 254	232 of 239	493	NCT00401726	Trial comparisons
Venlafaxine Extended Release (ER) vs Venlafaxine Extended Release (ER) Plus Dialogues: Number of Patients Responding Very Satisfied on Satisfaction With Depression Care Scale (SDCS)	160 of 254	138 of 239	493	NCT00401726	Trial comparisons
Lumateperone 42 mg vs Placebo: deaths from any cause	0 of 241	0 of 243	484	NCT04985942	Trial comparisons
Lumateperone 42 mg vs Placebo: serious adverse events	1 of 241	1 of 243	484	NCT04985942	Trial comparisons
Sertraline vs Placebo: serious adverse events	57 of 234	63 of 235	469	NCT00078286	Trial comparisons
Electroconvulsive Therapy (ECT) vs Ketamine Infusion: Number of Participants With Treatment Responses Based on the 16-item Quick Inventory of Depressive Symptomatology-Self-Report Scale (QIDS-SR-16)	70 of 170	108 of 195	365	NCT03113968	Trial comparisons

1 to 10 of 186

See all 186 comparisons in its trials

Papers from its trials356

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
40751860	RESULT	1	PubMed
40387497	RESULT	1	PubMed
39364684	RESULT	1	PubMed
38337458	RESULT	1	PubMed
38285446	RESULT	1	PubMed
37833734	RESULT	1	PubMed
37730990	RESULT	1	PubMed
37592013	RESULT	1	PubMed
37404968	RESULT	1	PubMed
37302533	RESULT	2	PubMed

1 to 10 of 356

See all 356 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0002050

GET https://conductscience.org/api/diseases/v1/MONDO_0002050/drugs?page=2

API reference For AI assistants